Moderna Topples, Threatening Its 50-Day Line, After A Key Vaccine Bites The Dust

Core Insights - Moderna's experimental CMV vaccine failed in a Phase 3 study, showing only 6% to 23% effectiveness, significantly below the target of 49.1% [2][3] - The company plans to continue a Phase 2 study for patients who have undergone bone-marrow transplants but will discontinue the congenital CMV study [4] - Moderna reiterated its expectation to achieve cash break-even by 2028, but the failure of the CMV program is expected to negatively impact cash flow [5] Company Performance - Following the study results, Moderna's stock fell approximately 2% to $26.34, potentially pushing it below its 50-day moving average [3] - Analysts have expressed low expectations for the CMV study, noting that it had previously missed an interim analysis [2] - The company is likely to report revenue at the lower end of its guidance of $1.5 billion to $2.2 billion for the full year 2025 due to reduced COVID-19 vaccination volumes [5] Analyst Ratings - William Blair analyst Myles Minter has a market perform rating for Moderna stock and has removed the CMV opportunity from his financial model [3][6] - Needham analyst Joseph Stringer has rated Moderna stock as a hold, indicating uncertainty about the reasons behind the trial's failure [4]